Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Audentes Therapeutics
Biotech
Astellas puts the cork back in $350M Xork deal with Cartesian
Astellas paid $10 million upfront and offered $340 million in biobucks to license Xork from Selecta.
Max Bayer
Mar 14, 2024 10:41am
Astellas' Pompe disease gene therapy placed on hold by FDA
Jun 27, 2022 9:03am
Astellas takes $170M hit as DMD gene therapy plan unravels
Apr 22, 2022 8:55am
Takeda taps Selecta for $1.1B gene therapy research pact
Oct 4, 2021 10:10am
Another death blights Astellas' $3B Audentes buy
Sep 14, 2021 3:45am
Astellas pauses gene therapy trial after low dose liver issue
Sep 1, 2021 7:20am
